Clinical Focus

• HIV/AIDS
• Infectious Disease

Administrative Appointments

• Acting Chief of Infectious Diseases, Stanford University, School of Medicine (2008 - present)

Professional Education

Community and International Work

• Rwanda/Stanford HIV Mentoring Program, Rwanda Africa 

Internet Links

• Stanford AIDS Clinical Trials Unit

Industry Relationships

Stanford is committed to ethical and transparent interactions with our industrial and other commercial partners. It is our policy to disclose payments (exclusive of travel support) from, and/or equity in, companies or other commercial entities to Stanford faculty of $5,000 or more in total value, as well as any equity in a privately held company, when the faculty member also has institutional responsibilities related to his or her interactions with the company. View Full Information

Current Research Interests

Dr. Zolopa’s research applies a variety of clinical epidemiologic methods in an effort to optimize antiretroviral therapy and understand the impact of drug resistance on response to ARV. Areas of focus include the clinical application of resistance testing in optimizing antiretroviral therapy, clinical cohorts, trials of antiretroviral therapies and population-based epidemiologic evaluation of HIV resistance and efficacy of ARV therapy. As the Principal Investigator of Stanford's NIH sponsored AIDS Clinical Trials Unit Dr. Zolopa is engaged in a variety of clinical trials focused on the optimization of ART both in the US and in income limited settings.
More recently studies focused on premature aging in HIV infected popultaions. This work will involve detailed immunologic evaluations and evaluation of end organ complications including heart disease, bone disease, renal disease and neuro-cognitive decline.
Finally, Dr. Zolopa is involved in HIV research in collaboration with the Rwandan Ministry of Health in Africa.

Clinical Trials

• ACTG 5128 Consent for Use of Stored Patient Specimens for Future Testing Recruiting
• ACTG 5001: Long-Term Data Collection From Participants in Adult AIDS Clinical Trials Recruiting
• A5281: A Phase I Randomized, Dose-Escalation Study to Evaluate the Safety and Immunogenicity of a Cytokine Enhanced HIV-1 Multi-Antigen (HIV MAG) pDNA Vaccine Delivered Intramuscularly Followed by in Vivo Electroporation (IM/EP) or Intramuscularly in HIHIV-1 Infected Adults Receiving ART Recruiting
• A5286: A Pilot Study of Rifaximin as a Modulator of Gut Microbial Translocation and Systemic Immune Activation in HIV-Infected Individuals with Incomplete CD4+ T-cell Recovery on Antiretroviral Therapy Recruiting
• A5296: Sevelamer Carbonate for Reducing Endotoxemia and Immune Activation: A Proof of Concept Study Recruiting

Publications

• Activity of elvitegravir, a once-daily integrase inhibitor, against resistant HIV Type 1: results of a phase 2, randomized, controlled, dose-ranging clinical trial. Zolopa AR, Berger DS, Lampiris H, Zhong L, Chuck SL, Enejosa JV, Kearney BP, Cheng AK. J Infect Dis. 2010; 201 (6): 814-22
• Association of HIV infection, demographic and cardiovascular risk factors with all-cause mortality in the recent HAART era. Cockerham L, Scherzer R, Zolopa A, Rimland D, Lewis CE, Bacchetti P, Grunfeld C, Shlipak M, Tien PC. J Acquir Immune Defic Syndr. 2010; 53 (1): 102-6
• Development of a didanosine genotypic resistance interpretation system based on large derivation and validation datasets. Assoumou L, Cozzi-Lepri A, Brun-Vézinet F, Degruttola V, Kuritzkes DR, Phillips A, Zolopa A, Miller V, Flandre P, Costagliola D. AIDS. 2010; 24 (3): 365-71
• Inflammation and mortality in HIV-infected adults: analysis of the FRAM study cohort. Tien PC, Choi AI, Zolopa AR, Benson C, Tracy R, Scherzer R, Bacchetti P, Shlipak M, Grunfeld C. J Acquir Immune Defic Syndr. 2010; 55 (3): 316-22
• International cohort analysis of the antiviral activities of zidovudine and tenofovir in the presence of the K65R mutation in reverse transcriptase. Grant PM, Taylor J, Nevins AB, Calvez V, Marcelin AG, Wirden M, Zolopa AR. Antimicrob Agents Chemother. 2010; 54 (4): 1520-5